Bortezomib Improves EFS, OS in T-Cell Lymphoblastic Lymphoma
Bortezomib improved event-free survival and overall survival in children and young adults with T-cell lymphoblastic lymphoma.
Bortezomib improved event-free survival and overall survival in children and young adults with T-cell lymphoblastic lymphoma.
Researchers sought to determine the dose and safety profile for mosunetuzumab administered for patients with aggressive and indolent relapsed or refractory B-NHLs.
Researchers sought to determine whether brentuximab vedotin with bendamustine would be effective in pediatric patients with relapsed or refractory Hodgkin lymphoma.
A retrospective study of patient data sought to determine if bone marrow infiltration is linked to adverse effect severity in patients with CD20-positive B-NHL.
Researchers sought to determine whether isatuximab would have responses in patients with T-ALL or T-LBL.
Researchers sought to determine whether the early use of FDG PET may help predict future failure with CAR-T therapy in patients with LBCL.
Researchers sought to determine whether using LF-radiotherapy would reduce excess long-term morbidity among patients with stage I-IIa classical Hodgkin lymphoma.
Researchers sought to determine the health-related quality of life of patients with classical Hodgkin lymphoma receiving pembrolizumab.
Researchers sought to determine whether the route of prophylaxis would impact CNS relapse in patients with certain aggressive B-cell non-Hodgkin lymphomas.
Researchers sought to determine whether CAR-T therapy with alloHCT would lead to durable remissions in patients with DLBCL who relapsed after prior autoHCT.